Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Upon completion of the merger, the Company has to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), into clinical-stage development for the treatment of patients with Type 2 diabetes.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: NPM-119
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Second Sight Medical Products
Deal Size: Undisclosed Upfront Cash: $55.0 million
Deal Type: Merger August 30, 2022
Details:
Results at 25 weeks exhibit bystander suppression by delivering only two antigens, indicating the mouse surrogate of RTX-T1D prevented or delayed disease caused by many autoantigens.
Lead Product(s): RTX-T1D
Therapeutic Area: Endocrinology Product Name: RTX-T1D
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Presented pre-clinical murine data demonstrating SC451 ability to make stem cell-derived hypoimmune pancreatic islet cells with robust function and hypoimmune pancreatic islet cells that evade immune detection and have the ability to regulate glucose levels.
Lead Product(s): SC451
Therapeutic Area: Endocrinology Product Name: SC451
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and function, thereby increasing insulin levels and controlling high glucose levels.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
BMF-219, as a single agent, demonstrated a significant reduction in HbA1C versus liraglutide and strong glucose tolerance and glycemic control. These effects were maintained even after dosing had stopped.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Under the agreement, Dr. Auchampach and his team will test Purnovate’s adenosine compounds in preclinical models with the goal of further validating the potential of Purnovate’s compounds as a treatment for diabetes and NASH.
Lead Product(s): Adenosine Analog
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Medical College of Wisconsin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 19, 2022
Details:
The partnership leverages iPSC-based beta cells from Evotec’s QRbeta initiative. Evotec reliably produces human iPSC-based beta cells in islet-like clusters in a quality controlled (“QC”) scalable bioreactor process.
Lead Product(s): iPSC-based Beta Cell Replacement Therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sernova Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 17, 2022
Details:
The JDRF award will fund efforts to investigate the use of NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab. The investigation will test this hypothesis in a preclinical model by combining anti-CD3 mAb treatment.
Lead Product(s): T1D Antigen-specific Nanoparticle,Teplizumab
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: JDRF
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Partnership May 10, 2022
Details:
SC451, hypoimmune stem-cell derived pancreatic islet cell therapy for patients with type 1 diabetes, transplanted intramuscularly may be capable of persisting and functioning in diabetic patients without immune suppression.
Lead Product(s): SC451
Therapeutic Area: Endocrinology Product Name: SC451
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
BMF-219 was multi-fold more potent and exerted greater cytotoxicity compared to clinical reversible menin inhibitors in DLBCL patient-derived ex vivo samples and over 99% cell lethality in MM cell lines with RAS mutations as a single agent.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
